GlassScriptPhysician profile
Heather Fitzpatrick
NPI 1912513763
$4,596.05
in general payments reported to CMS, 2019-2025
34 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $796 · 2023: $1,493 · 2024: $1,768 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,492 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,491.72 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.79 | 2021-2025 | |
| Novo Nordisk INC | $556.89 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $465.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $350.51 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $289.57 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $247.42 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $227.99 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $217.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $149.79 | 2022-2023 | Quviviq |
| Pfizer INC. | $124.57 | 2023-2024 | |
| Amgen INC. | $118.47 | 2022-2025 | Krystexxa, Evenity, Prolia |
| Horizon Therapeutics Plc | $112.95 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $104.58 | 2023-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $83.99 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.87 | 2023-2024 | Synjardy, Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.18 | 2024 | Xifaxan |
| Inspire Medical Systems, INC. | $56.31 | 2024 | Inspire |
| Esperion Therapeutics, INC. | $49.70 | 2024 | Nexletol |
| Teleflex LLC | $48.90 | 2024 | Urolift |
| Takeda Pharmaceuticals U.S.A., INC. | $46.62 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $43.48 | 2023 | Opsumit |
| Otsuka America Pharmaceutical, INC. | $36.82 | 2022-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $28.95 | 2024 | Gemtesa |
| Adlon Therapeutics L.P. | $25.94 | 2021 | |
| Novartis Pharmaceuticals Corporation | $25.63 | 2023 | |
| Watermark Medical, INC. | $20.24 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.66 | 2025 | |
| Amarin Pharma, INC. | $19.40 | 2021 | |
| Nevro Corp. | $16.19 | 2024 | Senza |
| Redhill Biopharma INC. | $16.16 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.90 | 2024 | Evkeeza |
| Currax Pharmaceuticals LLC | $14.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2024 | Zoryve |
| Biohaven Pharmaceuticals, INC. | $13.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.